Hormone therapy may lower risk for CVD among midlife women

Women in midlife with vasomotor symptoms who initiated menopausal hormone therapy, or MHT, during perimenopause or shortly after menopause had a 22% lower risk for CVD, new data show.Prior literature in this area is mixed, with studies capturing both beneficial and adverse impacts of MHT on cardiovascular health, according to Ziyuan Wang, PhD, an advisor pharmacoepidemiology at Eli Lilly and